Abstract
Introduction:
Faced with weak pipelines, poor R&D productivity, expiring patents, and public
and regulatory pressure over safety, major pharmaceutical companies are
turning to the biotech industry for innovation. Much as in the late 1990s, Big
Pharma is enthusiastically pursuing platform technologies and early-stage
clinical candidates through a mix of strategic alliances, partnerships, and
mergers and acquisitions
Get the Answers You Need to Shape Your Strategy
- Big Pharma has expressed renewed interest in platform technologies and
early-stage clinical candidates originating from biotechnology companies.
What types of deals are occurring most frequently between these industries?
What approaches to drug discovery are of most interest to pharmaceutical
companies? What clinical trial phase is receiving the most attention from Big
Pharma?
- In addition to the growing interest from pharmaceutical companies, many
biotechs are also now participating in high-value partnerships with other
biotechs to fund drug development. How do biotech-biotech deals differ from
those involving Big Pharma? In what ways do biotech companies' long- and
short-term goals correspond to or differ from those of pharmaceutical
companies?
- Consolidation of the pharmaceutical and biotech industries has continued,
with a recent surge in the number of mergers and acquisitions. What
resources do pharmaceutical companies look for in companies when they consider
acquisitions? What platforms or indications have been highlighted as areas of
interest by Big Pharma? What does the emergence of reverse mergers say about
the state of the market?
- As the biotechnology industry continues to mature, biotech companies will
face more and more of the issues that typically plague Big Pharma. What are
the key issues that biotech companies will face as they mature? How will these
issues impact the risk and success of biotech drug development?
Scope
- Deal activity, by drug discovery stage: a review of deals for
compounds in lead development; lead optimization; lead identifi cation; and
target identifi cation and validation
- Mergers and acquisitions: a review of high-value ($100 million+)
M&A deals involving biotech, including a look at reverse mergers
- Deal participants: an examination of pharma-biotech and
biotech-biotech deal activity
- Market outlook: our forecast for trends in biotech dealmaking for
2007 and beyond
View Cart
